![]() |
Skin
|
![]() |
Die österreichische Ausgabe der Zeitschrift steht Mitgliedern der ÖGDV mit Nachrichten, Mini-Reviews und Mini-Perspektiven, Berichten und Artikeln zur Verfügung. Die Artikel erscheinen in English und/oder Deutsch. |
![]() |
Verlag der Österreichischen Akademie der Wissenschaften Austrian Academy of Sciences Press
A-1011 Wien, Dr. Ignaz Seipel-Platz 2
Tel. +43-1-515 81/DW 3420, Fax +43-1-515 81/DW 3400 https://verlag.oeaw.ac.at, e-mail: verlag@oeaw.ac.at |
|
||||||||||||||||||||
|
DATUM, UNTERSCHRIFT / DATE, SIGNATURE
BANK AUSTRIA CREDITANSTALT, WIEN (IBAN AT04 1100 0006 2280 0100, BIC BKAUATWW), DEUTSCHE BANK MÜNCHEN (IBAN DE16 7007 0024 0238 8270 00, BIC DEUTDEDBMUC)
|

Skin 1/2026, pp. 42-43, 2026/03/19
Ausgabe 01/2026: März
Immune checkpoint inhibitors (ICIs) have improved survival in patients with advanced melanoma; however, a considerable number of patients do not respond, and side effects are common. Studies suggest that the gut microbiome may influence ICI outcomes, and certain bacteria and microbial functions have been linked to a positive response in some patient groups. However, the findings are inconsistent across studies, and no universal microbial biomarkers have been identified. Longitudinal and multi-omic analyses indicate that microbial dynamics may matter and that other body sites, such as the skin and the intratumoral environment, could also be relevant. More systematic research and testing of multiple hypotheses is needed before microbiome-based strategies may be reliably applied in clinical practice. Here, we summarize evidence supporting a connection between the hummicrobiome and the ICI response in melanoma.